News Agency
The Times

Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism

  • Written by PR Newswire

Submission of NDA to the NMPA is planned within 2023 at the earliest

SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3 China clinical trial for its innovative...

Read more: Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted...

Executive Recruitment And The Value Of Executive Recruitment Agencies In Modern Hiring

Finding the right leadership talent is one of the most important decisions an organisation can make. Strong leaders influence company culture, business performance, strategic direction, and long-term growth. As competition for experienced executives continues to increase, executive recruitment has become a... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion